Tegoprubart Delivers Insulin Independence for Type 1 Diabetics — FDA Must Not Delay This Breakthrough

A stunning new clinical trial shows tegoprubart could free Type 1 diabetics from insulin for good. The science is there. Now the question is whether regulators will get out of the way.

For the roughly 1.6 million Americans living with Type 1 diabetes, daily life is a relentless negotiation with a disease that never sleeps. Blood sugar checks. Carb counts. Insulin doses calculated to the unit. Emergency plans for a hypoglycemic episode at 2 a.m. This is not a condition that responds to diet changes or willpower — it is an autoimmune life sentence, one that costs patients and the healthcare system billions of dollars every year.

But a new clinical trial, reported this week by HCP Live, is changing that conversation in a dramatic way. Eledon Pharmaceuticals announced updated results from an investigator-initiated study at the University of Chicago Medicine Transplant Institute showing that a drug called tegoprubart — combined with islet cell transplantation — enabled every evaluable patient to achieve insulin independence. That is not a partial improvement. That is not “reduced insulin dependency.” That is complete, measurable freedom from insulin for patients who had been living with Type 1 diabetes for an average of more than three decades.

What the Science Actually Shows

The trial enrolled 12 adults with long-standing Type 1 diabetes. Of the 10 patients who were more than four weeks post-transplant at the time of reporting, all 10 achieved insulin independence. All 10 also recorded a hemoglobin A1C below 6.0% — a threshold that places them in essentially non-diabetic territory. The group’s mean HbA1c was approximately 5.35%.

For context: the American Diabetes Association recommends an HbA1c target of below 7.0% for most adults with diabetes. These patients are not just managing their condition more effectively. By clinical standards, they are no longer diabetic.

Tegoprubart works by selectively inhibiting CD40 ligand, a co-stimulatory molecule in T cell activation. In simpler terms, it prevents the immune system from attacking the transplanted islet cells — the insulin-producing cells being replaced. Crucially, it does this without the toxic side effects associated with traditional calcineurin inhibitors, the standard class of immunosuppressants used in transplant medicine.

No rejection episodes. No nephrotoxicity. No hypertension. No neurotoxicity. The results were presented by Dr. Piotr Witkowski at the Advanced Technologies and Treatments for Diabetes (ATTD) conference in Barcelona — one of the field’s leading international forums. By any measure, these are results that demand urgent attention.

Why This Matters for Millions of American Families

Type 1 diabetes is diagnosed frequently in childhood. It follows patients into school, into the workforce, into parenthood. It limits career options, complicates pregnancy, and shadows every meal, every workout, every late night. According to peer-reviewed data published in Diabetes Care, people with Type 1 diabetes incur average annual medical expenditures of approximately $19,736, of which a significant portion is directly attributable to the disease itself.

Multiply that burden across 1.6 million Americans, and the fiscal picture becomes sobering. This is not merely a personal health issue. It is a national economic reality — one that responsible policy should be eager and motivated to address.

More importantly, it is a quality-of-life issue. These are parents who cannot sleep soundly for fear of their child’s overnight blood sugar drop. They are workers who carry glucose tablets in every pocket. They are adults who have spent a lifetime planning their days around a disease that arrived uninvited.

A treatment that delivers genuine, sustained insulin independence is not just medical news. It is a restoration of personal freedom.

The Real Cost of Bureaucratic Delay

Here is where the story becomes a policy conversation, not just a scientific one.

Eledon Pharmaceuticals has announced it plans to seek FDA regulatory guidance on a path to market for tegoprubart in islet cell transplantation. That process could take years. And for every year that separates a proven breakthrough from an accessible treatment, hundreds of thousands of patients continue to carry a burden they may not need to bear.

The FDA plays a critical role in protecting public safety — no one serious disputes that. Rigorous safety and efficacy review is essential. But bureaucratic delay carries its own cost: in dollars, in diminished quality of life, and in the compounding burden placed on patients and their families who are watching the calendar while waiting for relief.

This trial produced zero rejection episodes, zero serious immunosuppression-related toxicities, and a 100% insulin independence rate among evaluable patients. The science is being vetted publicly at top-tier international conferences. Regulators should respond in kind — with urgency, transparency, and a clear and realistic timeline.

What Critics Are Saying — And Why They’re Not Entirely Wrong

No responsible observer should dismiss the limitations here. This is a small trial. Twelve participants does not constitute a revolution. Long-term data on tegoprubart’s sustained performance — two years, five years, a decade post-transplant — is not yet available. Islet cell transplantation itself is a complex procedure that requires a suitable donor and carries inherent surgical considerations.

Critics are right to ask for larger trials, more diverse patient populations, and longer follow-up windows. That is not obstruction — that is responsible science.

But informed skepticism becomes a problem when it curdles into indefinite bureaucratic delay. The trial was funded by Breakthrough T1D, one of the most credible and rigorous disease-focused nonprofits in the field. A second study has already been committed — this one extending research to T1D patients who also have chronic kidney disease, a particularly vulnerable population. The scientific community is moving forward deliberately and urgently. The regulatory apparatus should meet it there.

Private Innovation Leading Where Government Programs Lag

It is worth pausing to note what is driving this breakthrough. Not a federal mandate. Not a government-run research program. A private pharmaceutical company — Eledon Pharmaceuticals — working alongside a disease-focused nonprofit and a world-class academic medical institution.

This is what responsible, mission-driven innovation looks like in practice. Eledon is a focused biopharmaceutical company. Breakthrough T1D is a patient advocacy organization that has channeled decades of private fundraising into targeted, outcomes-driven research. Together, they have advanced a therapy to a point where the results are undeniable.

The instinct to look first to government for direction, funding, and solutions consistently underestimates what private enterprise and civil society deliver when properly incentivized and unimpeded by regulatory friction. Tegoprubart’s story, at this stage, is a compelling case study in exactly that principle.

A Turning Point — If We Act on It

“All 10 evaluable patients achieved insulin independence.”

That single sentence, embedded in a clinical trial update, may be among the most significant lines in diabetes research in years. Read it again. Understand what it means for 1.6 million Americans who wake every morning to a disease that takes before it gives.

This is not hype. This is peer-reviewed, publicly presented, rigorously collected clinical data. And it deserves the kind of national attention typically reserved for far lesser developments.

The Path Forward Is Clear

The promise of tegoprubart is real, measured, and grounded in serious science. A 100% insulin independence rate, HbA1c levels in the non-diabetic range, and a clean safety profile together represent a combination the field has been chasing for decades. The path to patients — additional trials, FDA engagement, and eventual market access — will require persistence and a regulatory environment that recognizes the cost of inaction alongside the cost of haste.

For the millions of Type 1 diabetics and their families who have managed a relentless disease for years, sometimes decades, the question is straightforward: How long will they have to wait?

That question deserves a real answer. And based on the science available today, the answer should be: not long.

Stay Informed. Stay Engaged.

This story will continue to develop as Eledon pursues its regulatory path and new trial data emerges. Share this article with someone living with Type 1 diabetes — or with anyone who believes that personal freedom includes freedom from preventable suffering. Independent journalism that tracks medical breakthroughs and holds regulators accountable depends on an engaged readership. Stay informed. Make noise. And demand that the people making policy decisions understand what is at stake.